CONCLUSIONS
nonsquamous NSCLC
This Phase III study has demonstrated that in patients with advanced nonsquamous NSCLC, BAT1706 shows clinical equivalence to EU‐bevacizumab in terms of efficacy, safety, PK, and immunogenicity, when administrated in combination with paclitaxel and carboplatin. These data add to the totality of evidence that BAT1706 is similar to reference bevacizumab.